智飛生物(300122.SZ):與中國科學院微生物研究所合作開發新型冠狀病毒疫苗
格隆匯2月2日丨智飛生物(300122.SZ)公佈,公司全資子公司安徽智飛龍科馬生物製藥有限公司(“智飛龍科馬”或“甲方”)與中國科學院微生物研究所(“微生物所”或“乙方”)於2020年1月29日簽訂了《合作意向框架協議》。
為積極應對當前疫情,加快2019-nCoV疫苗的開發,基於乙方已取得的相關技術祕密和經驗,甲方有意受讓並進行後續產業化開發2019-nCoV重組蛋白亞單位疫苗。雙方在簽訂正式技術轉讓合同前,共同簽訂本協議以儘快啟動合作。
中國科學院微生物研究所成立於1958年12月3日,其前身是中國科學院應用真菌研究所和中國科學院北京微生物研究室,目前已發展成為一個具有雄厚基礎、強大實力和廣泛影響的綜合性微生物學研究和微生物技術研發機構。
微生物所堅持“微生物、高科技、大產業”的戰略定位,面向工業升級、農業發展、人口健康和環境保護等國家重大需求,瞄準微生物學科的發展前沿,以微生物資源、微生物技術、病原微生物與免疫為主要研究領域,在研究微生物生物多樣性、基本生命特徵和生態功能的基礎上,努力創建從微生物資源開發、功能改造和利用、生物技術創新到成果轉化的自主研發體系,創建世界一流的微生物學研究中心和微生物生物技術研發基地。
2019-nCoV於2019年在武漢首次被發現,目前尚無有效疫苗被批准應用於人體。此次與微生物所簽訂合作協議,有利於加快2019-nCoV重組蛋白亞單位疫苗的開發,若項目能夠成功研發並順利實現產業化,將為民眾提供新型冠狀病毒免疫選擇和服務,同時為國家疾病預防控制貢獻力量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.